RxDoctor Payments Data

Sean Ryan, MD

Internal Medicine · Nashville, TNNPI 1740271402

Payments from drug & device makers

$739in general payments, 2019–2025

Across 12 payments — averaging $61.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$536
  • AstraZeneca$65
  • Astellas Pharma US Inc$39
  • Pfizer$23
  • Novo Nordisk$22
  • GSK$18
  • plus $36 from 3 others

What the payments were for

  • Travel & lodging$53673%
  • Food & beverage$20327%

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Stryker1$536
AstraZeneca3$65
Astellas Pharma US Inc2$39
Pfizer1$23
Novo Nordisk1$22
GSK1$18
Gilead1$16
Boston Scientific1$14
Bardy Diagnostics, Inc.1$7

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$739 in reported general payments places this provider in the 65th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$357,379
Medicare patients
558
Services billed
12,487

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban278$291,449
TrulicityDulaglutide105$131,122
OzempicSemaglutide110$127,671
JardianceEmpagliflozin111$109,682
XareltoRivaroxaban39$49,549
MounjaroTirzepatide36$36,354
Breo ElliptaFluticasone/Vilanterol42$27,551
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$21,958
Candesartan Cilexetil130$13,854
Advair HfaFluticasone Propion/Salmeterol32$11,045
RybelsusSemaglutide11$10,233
Atorvastatin Calcium725$9,654
SynthroidLevothyroxine Sodium127$8,719
FarxigaDapagliflozin Propanediol12$7,954
Fluticasone-SalmeterolFluticasone Propion/Salmeterol33$7,389

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid, Premarin$23$296,970345 claims
Novo NordiskOzempic, Rybelsus$22$137,904121 claims
GSKBreo Ellipta, Trelegy Ellipta$18$49,50858 claims
AstraZenecaFarxiga$65$7,95412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,216 internal medicine providers in Tennessee.

Other internal medicine in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →